---
title: "Gracell 生物技術股東批准阿斯利康合併協議。"
description: "Gracell 生物技術股東已經批准與阿斯利康的合併協議。該協議涉及合併的執行、交付和履行，使 Gracell 成為阿斯利康的全資子公司。此次批准獲得了會議上投票總數的 99.9% 支持。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/108247711.md"
published_at: "2024-02-20T13:00:42.000Z"
---

# Gracell 生物技術股東批准阿斯利康合併協議。

> Gracell 生物技術股東已經批准與阿斯利康的合併協議。該協議涉及合併的執行、交付和履行，使 Gracell 成為阿斯利康的全資子公司。此次批准獲得了會議上投票總數的 99.9% 支持。

Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today that during an extraordinary general meeting of shareholders (EGM) on February 19, 2024, shareholders voted in favor of the proposal to approve and authorize the execution, delivery, and performance of the Agreement and Plan of Merger. This agreement, dated December 23, 2023 (the "Merger Agreement"), involves the Company, AstraZeneca Treasury Limited, a private limited company incorporated in England and Wales ("Parent"), and Grey Wolf Merger Sub, a wholly owned subsidiary of Parent incorporated in the Cayman Islands ("Merger Sub"). The approval also covers the Plan of Merger to be filed with the Registrar of Companies of the Cayman Islands, as well as any other agreements or documents related to the Merger Agreement or delivered in connection with it. 根據併購協議約定的條款和條件，包括併購協議（包括合併）和附表 B 所附的《附帶價值權協議》，（統稱為 “交易”），公司作為一方參與了 “行動文件”，並完成了所 contempl 的交易。根據併購協議，根據開曼羣島《公司法（修訂版）》的適用規定，Merger Sub 將在合併的生效時間與公司合併，公司將繼續作為存續公司，併成為母公司的全資子公司（“合併”）。

公司總共 458,283,333 股普通股，每股面值為$0.0001（“普通股”），包括公司的美國存托股（“ADSs”），出席了 EGM，不論親自出席還是通過代理出席。每位股東每股普通股有一票。這些股份約佔公司在開曼羣島營業結束時所持有的普通股總數的 94.8%。 在 2024 年 1 月 8 日的股東大會記錄日期上，大約 99.9% 的總投票數贊成《合併協議》、《合併計劃》和相關交易。

### Related Stocks

- [AZN.US - 阿斯利康](https://longbridge.com/zh-HK/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | AstraZeneca Says US FDA Approves Calquence Combo for Certain Blood Cancer Patients | [Link](https://longbridge.com/zh-HK/news/276444179.md) |
| AstraZeneca PLC $AZN Shares Sold by Ontario Teachers Pension Plan Board | Ontario Teachers Pension Plan Board reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 41% in Q3, now holding 817,880  | [Link](https://longbridge.com/zh-HK/news/276339476.md) |
| Do Wall Street Analysts Like Ecolab Stock? | Do Wall Street Analysts Like Ecolab Stock? | [Link](https://longbridge.com/zh-HK/news/276322789.md) |
| Daiichi Sankyo and AstraZeneca get EU validation for Enhertu use | Daiichi Sankyo and AstraZeneca have received validation from the European Medicines Agency for their application to exte | [Link](https://longbridge.com/zh-HK/news/276408087.md) |
| 10:12 ETThe Michael J. Fox Foundation Releases New Care Partner Guide to Support Families Living with Parkinson's | The Michael J. Fox Foundation has released a new digital guide titled "Facing Parkinson's Together" to support care part | [Link](https://longbridge.com/zh-HK/news/276457960.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。